Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy

Martine De Vos,Edouard Louis,Jørgen Jahnsen,Jo G P Vandervoort,Maja Noman,Olivier Dewit,Geert DʼHaens,Denis Franchimont,Filip Baert,Roald Torp,Magne Henriksen,Philippe M R Potvin,Philippe Van Hootegem,Pieter Hindryckx,Tom G. Moreels,Arnaud Collard,Lars Normann Karlsen,Eirik Kittang,Guy Lambrecht,Tore Grimstad,Jonas Koch,Idar Lygren,Jean-Claude R J Coche,Fazia Mana,André Van Gossum,Jacques Belaiche,Cool M,Fernand Fontaine,Jean-Marc Maisin,Vinciane Muls,Bart Neuville,Dirk Staessen,Gert Van Assche,Thomas de Lange,Inger Camilla Solberg,Bert Vander Cruyssen,Severine Vermeire

Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy

2013

Fecal calprotectin can be used in daily practice to monitor patients with UC receiving infliximab maintenance therapy. Two consecutive measurements >300 mg/kg is more specific than a single measurement for predicting relapse.

Keywords:

Infliximab
Calprotectin
Ulcerative colitis
Immunology
Maintenance therapy
Physical therapy
Medicine
Gastroenterology
Sigmoidoscopy
Colitis
Surgery
Young adult
Prospective cohort study
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

144

Citations